-

Umpqua Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Umpqua Holdings Corporation Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – UMPQ

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Umpqua Holdings Corporation (NASDAQ: UMPQ) to Columbia Banking System, Inc. is fair to Umpqua shareholders. Under the terms of the agreement, Umpqua shareholders will receive 0.5958 of a share of Columbia stock for each Umpqua share they own. Upon completion of the transaction, Umpqua shareholders will own approximately 62% of the combined company.

Halper Sadeh encourages Umpqua shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

The investigation concerns whether Umpqua and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Umpqua shareholders; (2) determine whether Columbia is underpaying for Umpqua; and (3) disclose all material information necessary for Umpqua shareholders to adequately assess and value the merger consideration. On behalf of Umpqua shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Umpqua shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contacts

Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

Halper Sadeh LLP

NASDAQ:UMPQ

Release Versions

Contacts

Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

More News From Halper Sadeh LLP

AVO Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Mission Produce, Inc. is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Mission Produce, Inc. (NASDAQ: AVO) and Calavo Growers, Inc. is fair to Mission shareholders. Upon completion of the proposed transaction, Mission shareholders are expected to own approximately 80.3% of the combined company. Halper Sadeh encourages Mission shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212)...

CVGW Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Calavo Growers, Inc. is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Calavo Growers, Inc. (NASDAQ: CVGW) to Mission Produce, Inc. for $14.85 in cash and 0.9790 shares of Mission for each share of Calavo is fair to Calavo shareholders. Halper Sadeh encourages Calavo shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com....

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary duties to shareholders. If you currently own BioXcel stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about...
Back to Newsroom